Table 1.
Global viral screens |
Influenza |
Genomics | [2, 3••, 4, 5, 6•, 7, 81, 82] |
Proteomics and genomics |
[15, 16] |
||
HIV |
Genomics | [9, 8••, 83, 10, 11, 12, 84, 85] | |
Phosphoproteomics cellular reprogramming through HIV | [26•] | ||
Proteomics |
[13••] |
||
Other viruses |
Genomics | HCV [86, 87] Dengue [88] WNV [89] |
|
Proteomics | KSHV [14] Herpesvirus [90] |
||
Proteomics and genomics |
HCV [17] |
||
Effectors of antiviral response |
Genomics | HCV, YFV, WNV, chikungunya virus, Venezuelan equine encephalitis virus, HIV [63••] various ds DNA, (+)ssRNA, (−)ssRNA viruses [19] VSV, MHV-68 [91] |
|
Genomics combined with IFN stimulation | HCV [92] HCV [93] |
||
Proteomics and genomics |
Many different RNA and DNA virus ORFs [18] |
||
Cellular reprogramming/rewiring through viruses |
Phospho-proteomics | HIV [26•] | |
Proteomics |
HPV, EBV, Ad5 and PyV [94] |
||
Innate immune response pathway members affecting viral replication |
Cytosolic DNA pathway |
Proteomics and genomics |
HIV [20] |
Type I interferon regulation |
Proteomics and genomics |
VSV, Sendai, HSV [23] |
|
TLR pathway |
Genomics | Sendai [22] | |
Transcriptmomics, genetic perturbations, phosphoproteomics |
EMCV, NDV, VSV, Influenza [21] |
||
In vivo screening approach | Genomics | [75] |